Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing ...

Research analysts at William Blair issued their Q1 2026 earnings estimates for shares of argenx in a research note issued on ...

Equities researchers at William Blair issued their Q4 2026 earnings estimates for argenx in a report released on Monday, ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition that leads to reddening of the skin and the formation of painful and intensely itchy chronic lesions and blisters ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 ...

Autoimmune bullous diseases are often associated with significant morbidity and some can even cause mortality, if left untreated. Multiple therapies are now available to treat these blistering ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

From wetting the bed to acne, we have crunched the numbers on the success rate of every single disability claim. It comes ...